About: Early use of tocilizumab in the prevention of adult respiratory failure in SARS‐CoV‐2 infections and the utilization of interleukin‐6 levels in the management

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Early use of tocilizumab in the prevention of adult respiratory failure in SARS‐CoV‐2 infections and the utilization of interleukin‐6 levels in the management Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Early use of tocilizumab in the prevention of adult respiratory failure in SARS‐CoV‐2 infections and the utilization of interleukin‐6 levels in the management
Creator	Hassan, Ali Fernando, \| Nouf, \| Antony, Suresh Rey, Del Muhammad, \| Almaghlouth, K Antony, J Arian, U Bharat, \| Davis, Michelle Davis, Monique Fahad Omar, \| Guevara, Roberto Nishaal, \| Prakash, V
Source	Medline; PMC
abstract	BACKGROUND: Respiratory failure in severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection appears related to cytokine release syndrome (CRS) that often results in mechanical ventilation (MV). We investigated the role of tocilizumab (TCZ) on interleukin‐6 (IL‐6) trends and MV in SARS‐CoV‐2 patients. METHODS: In this longitudinal observational study, 112 patients were evaluated from 2/1/2020 ‐ 5/31/2020. TCZ was administered followed by methylprednisolone to patients with > 3L oxygen (O2) requirement and pneumonia severity index (PSI) score ≤ 130 with CT scan changes. IL‐6, C‐reactive protein (CRP), ferritin, lactate dehydrogenase (LDH), D‐dimer, and procalcitonin were monitored on days 0, 3, and 6 of therapy. Statistical analyses were performed with significance ≤ 0.05. RESULTS: 80/112 SARS‐CoV‐2‐positive patients (45 males, 56.96%; 34 females, 43.04%) were included in this study. Seven patients expired (8.75%) and nine patients required MV (11.25%). Median IL‐6 levels pre‐administration of TCZ was 342.50 (78.25 ‐ 666.25) pg/mL compared to post‐administration on day 3 (563; 162 ‐ 783) pg/mL (P < 0.00001). On day 6, the median dropped to 545 (333.50 ‐ 678.50) pg/mL compared to day 3 (P = 0.709). CRP, ferritin, LDH, and D‐dimer levels were reduced following TCZ therapy. CONCLUSIONS: Early use of TCZ may reduce the need for MV and decrease CRP, ferritin, LDH, and D‐dimer levels. The sequential use of methylprednisolone for 72 hours seems to potentiate the effect and prolong the suppression of the cytokine storm. IL‐6 levels may be helpful as a prognostic tool. This article is protected by copyright. All rights reserved.
has issue date	2020-07-09(xsd:dateTime)
bibo:doi	10.1002/jmv.26288
bibo:pmid	32644254
has license	no-cc
sha1sum (hex)	8f93ef30c855a94f65b5d1fd04f0ee59f83e4cdf
schema:url	https://doi.org/10.1002/jmv.26288
resource representing a document's title	Early use of tocilizumab in the prevention of adult respiratory failure in SARS‐CoV‐2 infections and the utilization of interleukin‐6 levels in the management
has PubMed Central identifier	PMC7361804
has PubMed identifier	32644254
schema:publication	J Med Virol
resource representing a document's body	covid:8f93ef30c855a94f65b5d1fd04f0ee59f83e4cdf#body_text
is schema:about of	named entity 'SARS-CoV-2' named entity 'cytokine release syndrome' named entity 'mechanical ventilation' named entity 'Background' named entity 'prevention' named entity 'infections' named entity 'Respiratory failure' named entity 'IL-6' named entity 'CRS' named entity 'respiratory failure' named entity 'corticosteroid' named entity 'SARS-CoV-2' named entity 'IL-6' named entity 'D-dimer' named entity 'statistical significance' named entity 'observational study' named entity 'comorbid conditions' named entity 'IL-6' named entity 'complete metabolic panel' named entity 'ivermectin' named entity 'trans' named entity 'chemokine' named entity 'cardiomyopathy' named entity 'CRP' named entity 'LDH' named entity 'anti-IL-6' named entity 'hypertension' named entity 'steroids' named entity 'receptor' named entity 'inflammatory markers' named entity 'bacterial infection' named entity 'normal range' named entity 'CRP' named entity 'SARS-CoV-2' named entity 'steroids' named entity 'CRP' named entity 'LDH' named entity 'Stata' named entity 'SARS-CoV-2' named entity 'remdesivir' named entity 'end-stage' named entity 'IL-6' named entity 'symptom' named entity 'meta-analysis' named entity 'summary statistics' named entity 'inflammatory state' named entity 'steroids' named entity 'CRP' named entity 'Wilcoxon signed-rank test' named entity 'steroids' named entity 'intubation' named entity 'cytokine storm' named entity 'P-value' named entity 'coinfections' named entity 'T-cell' named entity 'medical history' named entity 'IL-6' named entity 'immune cells' named entity 'hypoxemia' named entity 'rheumatoid arthritis' named entity 'Hispanic' named entity 'IL-6' named entity 'PCR' named entity 'El Paso' named entity 'LDH' named entity 'D-dimer'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software